Marathon Pharmaceuticals · SCN9A · Small Molecule
lidocaine hydrochloride is a small molecule developed by Marathon Pharmaceuticals. It is approved for therapeutic indications via injectable (others) or intradermal injection.
| Brand Names | 3268, lignocaine, Anesiva, ALGRX 3268 |
| Company | Marathon Pharmaceuticals |
| Drug Class | Small Molecule |
| Molecular Target | SCN9A |
| Route | Injectable (Others), Intradermal Injection |
| Status | Approved |
lidocaine hydrochloride acts on 1 molecular target:
| SCN9A | sodium voltage-gated channel alpha subunit 9 (SFNP, GEFSP7) |
lidocaine hydrochloride is developed for 2 unique indications across 1 therapeutic area.
| Therapeutic Area | Condition | Phase |
|---|---|---|
| Nervous system disorders | Anaesthesia | ✓ Approved |
| Nervous system disorders | Sensory loss | ✓ Approved |
Reena
Cota Letícia de Oliveira LO, Malacarne Bruno Dondoni BD, Dias Lucas Antunes LA, Pinho Neto Antônio Catunda AC et al.
The selectivity of diagnostic analgesia of the digital flexor tendon sheath (DFTS) in horses remains debated. This study aimed to determine whether intrasynovial administration of 2% lidocaine into the DFTS increases the mechanical nociceptive threshold (MNT) of the dorsal lamellar stratum, sole, coronary band and heel bulbs, with correct placement confirmed by contrast tenography. Six healthy horses with no clinical or radiographic distal limb abnormalities were used. Forelimbs were randomly assigned, with one limb receiving 2% lidocaine and the contralateral limb receiving lactated Ringer's solution via the palmar pastern approach to the DFTS; both solutions were mixed with radiographic contrast to confirm accurate placement. MNT was measured in 10-foot regions using a portable pressure dynamometer before and at predefined time points up to 4 hours after DFTS injection. Data were compared using Friedman and Wilcoxon tests (p < 0.05). No significant differences in MNT were observed over time or between groups. MNT values rarely exceeded 1-kg force, and medians in both groups showed only minor fluctuations, remaining close to 0.5-kg force across the evaluated foot regions. Under the conditions of this study, contrast-confirmed intrasynovial administration of 2% lidocaine into the DFTS did not produce detectable desensitisation of the evaluated foot regions in clinically normal horses.
Lorenzo Isadora Alves IA, Cunha Lucas Daniel Lago Lopes LDLL, Nascimento Allen Matheus da Silva AMDS, Monteiro Rhayane da Conceição RDC et al.
Conditioned pain modulation (CPM) assesses descending pain inhibition in humans and has been shown to be clinically relevant. However, the possible contribution of the CPM response to the efficacy of local anesthetics remains poorly understood. This study aimed to evaluate the association between the CPM response and the efficacy of topical anesthesia applied to the trigeminal region in females with chronic orofacial pain and healthy participants. Thirty-five females with painful temporomandibular disorder (TMD) and twenty healthy females were included. Somatosensory sensitivity of the masseter region was assessed at baseline and after the application of 4% lidocaine and placebo creams in three separate sessions. A sequential CPM protocol was assessed at baseline. The test stimulus (TS) was the pressure pain threshold of the anterior temporalis, and the conditioning stimulus was immersion of the forearm in hot water for 1 minute. CPM magnitude was calculated as the relative change between the unconditioned and conditioned TS, which was correlated with the relative changes in somatosensory sensitivity between the lidocaine/placebo and baseline sessions. The significance level was set at 0.2% following a Bonferroni correction (p = 0.002). There was a moderate, positive correlation (r = 0.54; p = 0.001) between the relative change in the cold detection threshold in the lidocaine session and CPM for participants with chronic painful TMD. There was no correlation between the degree of anesthesia and CPM in healthy females. The efficiency of descending pain inhibition may influence the effectiveness of topical anesthesia in patients with chronic orofacial pain.
Liu Wei W, Jiang Ronghan R, Liu Tiancun T, Yin Xiaojie X et al.
Aqueous zinc-ion batteries (AZIBs) are attractive for large-scale energy storage because of their intrinsic safety and low cost. However, the practical utilization of AZIBs is limited by dendrite growth, hydrogen evolution, and interfacial corrosion. Here, hydroxylamine hydrochloride (HH) is introduced as a multifunctional electrolyte additive to regulate the Zn/electrolyte interface and Zn2+ transport. The electrolyte micro-environment can be optimized by HH additive with polar N- and O-based sites that interact with Zn ions and alter interfacial adsorption on the Zn surface. Electrochemical measurements have demonstrated the uniform Zn nucleation enhancement and suppressed hydrogen evolution and corrosion together with improved interfacial kinetics. Compared to pristine electrolyte, the Zn2+ transference number increases from 0.23 to 0.44, while the apparent interfacial desolvation activation energy decreases from 36.86 to 28.16 kJ mol-1. Consequently, symmetric Zn cells using HH-ZSO can stably cycle for more than 500 h at 5 mA cm-2 and 3 mAh cm-2, and asymmetric cells deliver an average coulombic efficiency of 99.67%. The corresponding full-cell tests also show improved cycling performance and slow capacity decay. These results establish HH as a simple molecular-scale electrolyte modifier for stabilizing aqueous Zn metal anodes.
Schmidt Erica E, Guedes Alonso G P AGP, Ventura Beth A BA, Cramer Gerard G et al.
Local anesthetic nerve blocks are widely used to reduce pain during the disbudding procedure. In dairy calves, lidocaine is the standard choice because it is fast-acting and inexpensive. However, in goat kids, lidocaine's efficacy is constrained by its short-acting duration, narrow safety margin, and challenges in administration. Longer-acting anesthetics have been shown to improve pain control in other species. Our objective was to describe the latency to and duration of desensitization for buffered lidocaine (BL), bupivacaine (BUP), and bupivacaine liposome injectable suspension (BLIS) for a cornual nerve block in goat kids. Twenty-four kids (5 ± 2 d old) met study inclusion and retention criteria and were randomly assigned to one of 3 treatments (n = 8/group). A single horn bud was anesthetized with 1 mL of anesthetic divided equally between the cornual branches of the infratrochlear and lacrimal nerves. A nerve stimulator was used to assess baseline sensitivity before and at predefined intervals after treatment to assess latency to (2.5, 5, 6, 7, 8, 9, 10, 12.5, 15 min) and duration of (BL and BUP every 0.25 h; BLIS at 0.5, 1, 2, 4, 6, 8, 24, 48, 72 h) desensitization. All treatments achieved a complete cornual nerve block within 8 min after injection (BL: 5-6 min, BUP: 5-7 min, BLIS: 5-8 min), demonstrating a similar latency. The duration of desensitization varied among treatments. The BLIS lasted the longest (8-72 h), although the number of desensitized kids decreased over time (n = 8 at 6 h; n = 5 at 8 h; n = 1 between 24 and 72 h). In contrast, desensitization with BUP lasted 1.75 to 3.5 h (n = 8 at 1 h; n = 6 at 1.75 h; n = 4 at 2.25 h; n = 2 at 3.25 h), whereas BL offered the shortest period of desensitization, lasting 1 to 2.25 h (n = 6 at 1 h; n = 1 at 1.75 h). Our findings suggest that BLIS offers the greatest potential for extended pain relief without compromising the latency to desensitization.
Long Liuya L, Zhu Wenxiong W, Yuan Yifeng Y, Liu Tao T et al.
Objective To observe the clinical efficacy and safety of Sanju Lihe decoction combined with low-intensity pulsed ultrasound (LIPUS) in the treatment of type ⅢA prostatitis of qi stagnation and blood stasis pattern. Methods From September 2024 to December 2025, a total of 204 patients with type ⅢA prostatitis of qi stagnation and blood stasis pattern treated at the First Hospital of Hunan University of Chinese Medicine were enrolled and randomly divided equally into a control group and a treatment group. The control group received tamsulosin hydrochloride sustained-release capsules, moxifloxacin hydrochloride tablets, Sanju Lihe decoction, and health education. The treatment group was additionally treated with LIPUS on the basis of the control regimen. The treatment course lasted 4 weeks. During the treatment period, the dropped and excluded cases were recorded. Eventually, 195 cases were completed in the study, including 98 cases in the control group and 97 cases in the treatment group. The National Institutes of Health Chronic Prostatitis Symptom Index (NIH-CPSI), 5-item International Index of Erectile Function (IIEF-5), Self-Rating Anxiety Scale (SAS), Self-Rating Depression Scale (SDS), traditional Chinese medicine (TCM) syndrome scores, uroflowmetry parameters (Qmax, Qave), grading of leukocytes and lecithin bodies in expressed prostatic secretions, clinical efficacy, and follow-up outcomes were compared between the two groups before and after treatment. Results After treatment, NIH-CPSI scores, TCM syndrome scores, and SAS/SDS scores were improved in both groups compared with baseline (P<0.05). The improvements in NIH-CPSI, IIEF-5, SAS, Qmax, Qave, and leukocyte grading in prostatic secretions were significantly better in the treatment group than those in the control group (P<0.05). No significant differences were observed between the two groups in SDS scores, TCM syndrome scores, or lecithin body grading in prostatic secretions after treatment (P>0.05). The total effective rate was 77.55% in the control group and 92.78% in the treatment group, with a significantly higher rate in the treatment group (P<0.05). At the 4-week follow-up after treatment, NIH-CPSI scores remained lower in the treatment group than in the control group (P<0.05). No serious adverse events occurred in either group during treatment. Conclusion On the basis of conventional medication and health education, Sanju Lihe decoction combined with LIPUS further relieves pain and voiding symptoms, improves sexual function, anxiety status, and uroflowmetry, and alleviates local prostatic inflammation in patients with type ⅢA prostatitis of qi stagnation and blood stasis pattern. The regimen is safe and worthy of clinical application.
+9996 more articles available with a free account
Sign up free to view all articles →